Compare Bristol-Myers Squibb Co (BMY) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Prudential Financial Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.78 (market cap $129.94B), while Prudential Financial Inc trades at $122.48 (market cap $42.20B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.1× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.58%). Which is the better fit depends on your goals.
| BMY | PRU | |
|---|---|---|
Market Cap | $129.94B | $42.20B |
Sector | Health | Financials |
52-Week High | $65.89 | $123.93 |
52-Week Low | $42.60 | $92.00 |
Enterprise Value | $163.92B | $70.98B |
Dividend Yield | 3.96% | 4.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
PRU trades at $122.34, up 0.19% today, with a bullish technical signal from moving averages and support near $122. Recent Q2 2026 earnings beat estimates at $4.08 EPS, driven by strong PGIM and international performance. The company maintains a solid net income margin of 6.04% and ROE of 12.46%, with a dividend of $1.40 declared for September 2026. Revenue trends show growth from 2022 lows, reaching $61.0B in 2025.
Outlook is cautiously optimistic with earnings momentum and strategic focus on capital-light operations, but risks include sensitivity to interest rates and China regulatory news. Analysts are mixed with a $113.11 consensus target below current price, suggesting limited upside. Institutional holdings grew, as seen with Assenagon's 379.8% stake increase in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
